Foghorn Therapeutics Reports Discontinuation of P-I Clinical Trial for FHD-286 in Metastatic Uveal Melanoma (mUM)
Shots:
- The P-I clinical trial evaluates the safety, efficacy & tolerability of FHD-286 (2.5/5.0/7.5/10.0mg qd or 10.0/15.0/17.5/20.0/22.5mg qw) in patients (n=73) with mUM that have been treated with a median of two prior therapies across 9 different cohorts
- Of the 47 target lesion evaluable patients, 1 depicted a durable response & remained on treatment for ≥16mos., 9 showed a stable disease & 8 had tumor reductions in target lesions. The clinical study was further supported by the reduction in ctDNA
- As per the results from the P-I clinical trial, Foghorn intends to discontinue the trial in mUM & expects to initiate a P-I clinical trial evaluating FHD-286 + decitabine/cytarabine in r/r AML patients by Q3’23
Ref: Foghorn | Image: Foghorn
Related News:- Lilly Collaborates with Foghorn to Develop Novel Oncology Therapies for the Treatment of Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
